Pharmaceutical Executive January 23, 2024
Staff

The Osteoboost device has been shown to slow the loss of bone strength and density in postmenopausal women with osteopenia.

The FDA has cleared Bone Health Technologies’ wearable belt device for the treatment of low bone density in postmenopausal women. The regulatory action makes the Osteoboost belt the first non-pharmacological device-based prescription therapy to gain approval in the United States for the treatment of osteopenia.1

“[The] groundbreaking decision represents the first non-pharmacological therapy approved to treat this widespread and serious condition. With Osteoboost, we have a new treatment option—free of serious adverse events—that taps into the body’s natural mechanism to stimulate bone growth,” Bone Health Technologies CEO Laura Yecies said in a press release. “Women’s health...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Digital Health, FDA, Govt Agencies, Patient / Consumer, Provider, Technology, Wearables
Key Benefits of CGM Technology
'We can nip a pandemic in the bud with smartwatches'
Flattening the curve: How smartwatches could help stop a pandemic before it even begins
Unlocking the power of sensor data in type 2 diabetes care
Google’s Pixel Watch 3 Loss of Pulse Detection Feature Receives FDA Clearance

Share This Article